Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000324227 | SCV000339636 | uncertain significance | not provided | 2016-02-25 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000814374 | SCV000954782 | uncertain significance | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2022-11-09 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 286277). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CACNA1A protein function. This missense change has been observed in individual(s) with episodic ataxia and migraine (PMID: 34806130). This variant is present in population databases (rs768768744, gnomAD 0.002%). This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 390 of the CACNA1A protein (p.Asn390Lys). |
Fulgent Genetics, |
RCV002494856 | SCV002782317 | uncertain significance | Episodic ataxia type 2; Spinocerebellar ataxia type 6; Migraine, familial hemiplegic, 1; Developmental and epileptic encephalopathy, 42 | 2022-02-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000324227 | SCV002822527 | uncertain significance | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | CACNA1A: PP2, PP3 |